2,4-Diisopropyl-6-methyl-1,3,5-triazin | 59101-60-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 2,4-Diisopropyl-6-methyl-1,3,5-triazin
• 英文别名: 2-Methyl-4,6-diisopropyl-1,3,5-triazin；2,4-diisopropyl-6-methyl-[1,3,5]triazine；2-Methyl-4,6-di(propan-2-yl)-1,3,5-triazine
• CAS: 59101-60-9
• 化学式: C₁₀H₁₇N₃
• 分子量: 179.265
• InChiKey: YFUVNMQKNAQKMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  异丁醛 、 乙醛 生成 2,4-Diisopropyl-6-methyl-1,3,5-triazin
  参考文献：
  名称：

  BECKER B. F.; FRITZ H. P., CHEM. BER. , 1976, 109, NO 4, 1346-1352 D2-#5#; #99# #2#4

  摘要：

  DOI：

文献信息

• ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
  申请人：UNIVERSAL DISPLAY CORPORATION

  公开号：US20200369699A1

  公开（公告）日：2020-11-26

  Provided is a compound comprising a first ligand L A of

  提供一个包含第一配体L的化合物。
• INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS
  申请人：Aronov Alex

  公开号：US20090048250A1

  公开（公告）日：2009-02-19

  The present invention provides compounds of formula I: These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK2, CDK2, MK2, SRC, SYK, and Aurora-2. Accordingly, compounds and compositions of the invention are useful for treating or lessening the severity of a variety of disorders, including, but not limited to, heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases and viral diseases.

  本发明提供了I式化合物：这些化合物及其药学上可接受的组合物通常用作激酶抑制剂，特别是作为PRAK、GSK3、ERK2、CDK2、MK2、SRC、SYK和AuroRA-2的抑制剂。因此，本发明的化合物和组合物可用于治疗或减轻各种疾病的严重程度，包括但不限于心脏疾病、糖尿病、阿尔茨海默病、免疫缺陷病、炎症性疾病、过敏性疾病、自身免疫性疾病、破坏性骨疾病（如骨质疏松症）、增生性疾病、传染病和病毒性疾病。
• INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK)
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20140309249A1

  公开（公告）日：2014-10-16

  The present invention provides novel compounds according to Formula (I): where Ring A, Ring B, X, L 1 , L 2 , R A , R C , R D , R E , m, n, and p are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of human diseases associated with kinase activity, for example, proliferative diseases, neurodegenerative diseases, metabolic disorders, inflammatory diseases, and cardiovascular diseases.

  本发明提供了一种新的化合物，其化学式如下（I）：其中环A、环B、X、L1、L2、RA、RC、RD、RE、m、n和p的定义如本文所述。本发明的化合物被认为对与激酶活性相关的多种人类疾病的预防和治疗有用，例如增生性疾病、神经退行性疾病、代谢性疾病、炎症性疾病和心血管疾病。
• INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20160122323A1

  公开（公告）日：2016-05-05

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了式（I）的新型化合物及其药学上可接受的盐、溶剂合物、水合物、多晶形、共晶体、互变异构体、立体异构体、同位素标记衍生物、前药和其组合物。本发明还提供了使用所述创新化合物或组合物治疗或预防增殖性疾病（例如，癌症（例如，白血病、淋巴瘤、黑色素瘤、多发性骨髓瘤、乳腺癌、尤因氏肉瘤、骨肉瘤、脑癌、神经母细胞瘤、肺癌）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫疾病）的方法和试剂盒。使用本发明的化合物或组合物治疗患有增殖性疾病的受试者，可以抑制激酶的异常活性，例如细胞周期依赖性激酶（CDK）（例如细胞周期依赖性激酶7（CDK7）），从而在受试者中诱导细胞凋亡和/或抑制转录。
• Compounds for treating cancer
  申请人：Bicycle Therapeutics Limited

  公开号：US10624968B2

  公开（公告）日：2020-04-21

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。